Edward Morrow Atkinson Iii Vertex Pharmaceuticals Inc (VRTX) insider trading activity

Edward Morrow Atkinson Iii is EVP, Chief Technical Ops. Off. of VERTEX PHARMACEUTICALS INC . Currently has a direct ownership of 19,352 shares of VRTX, which is worth approximately $9.28 Million. The most recent transaction as insider was on Feb 27, 2025, when has been sold 2,650 shares (Common Stock) at a price of $475.34 per share, resulting in proceeds of $1,259,651. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 19.4K

21.16% 3M change

21.16% 12M change

Total Value Held $9.28 Million

Edward Morrow Atkinson III Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 27 2025	SELL Open market or private sale	$1,259,651 $475.34 p/Share	2,650 Reduced 12.04%	19,352 Common Stock
Feb 26 2025	SELL Payment of exercise price or tax liability	$1,190,392 $479.61 p/Share	2,482 Reduced 10.14%	22,002 Common Stock
Feb 25 2025	SELL Open market or private sale	$849,838 $480.95 p/Share	1,767 Reduced 6.73%	24,484 Common Stock
Feb 24 2025	SELL Payment of exercise price or tax liability	$800,311 $483.28 p/Share	1,656 Reduced 5.93%	26,251 Common Stock
Feb 14 2025	SELL Payment of exercise price or tax liability	$708,630 $463.46 p/Share	1,529 Reduced 5.19%	27,907 Common Stock
Feb 12 2025	BUY Grant, award, or other acquisition	-	6,211 Added 17.42%	29,436 Common Stock
Feb 11 2025	SELL Open market or private sale	$803,323 $459.83 p/Share	1,747 Reduced 7.0%	23,225 Common Stock
Feb 10 2025	SELL Payment of exercise price or tax liability	$409,950 $467.98 p/Share	876 Reduced 3.39%	24,972 Common Stock
Feb 04 2025	BUY Grant, award, or other acquisition	-	9,876 Added 27.65%	25,848 Common Stock
Jun 12 2024	SELL Open market or private sale	$3,483,664 $478.0 p/Share	7,288 Reduced 31.33%	15,972 Common Stock
Jun 11 2024	SELL Payment of exercise price or tax liability	$3,288,895 $481.96 p/Share	6,824 Reduced 22.68%	23,260 Common Stock
May 14 2024	BUY Grant, award, or other acquisition	-	14,112 Added 31.93%	30,084 Common Stock
Feb 26 2024	SELL Open market or private sale	$375,893 $425.7 p/Share	883 Reduced 5.24%	15,972 Common Stock
Feb 23 2024	SELL Payment of exercise price or tax liability	$714,180 $431.79 p/Share	1,654 Reduced 8.94%	16,855 Common Stock
Feb 21 2024	SELL Open market or private sale	$506,545 $421.77 p/Share	1,201 Reduced 6.09%	18,509 Common Stock
Feb 20 2024	SELL Open market or private sale	$337,052 $420.79 p/Share	801 Reduced 3.91%	19,710 Common Stock
Feb 20 2024	SELL Payment of exercise price or tax liability	$473,152 $420.58 p/Share	1,125 Reduced 5.2%	20,511 Common Stock
Feb 16 2024	SELL Payment of exercise price or tax liability	$636,439 $424.01 p/Share	1,501 Reduced 6.49%	21,636 Common Stock
Feb 12 2024	SELL Open market or private sale	$383,679 $420.24 p/Share	913 Reduced 3.8%	23,137 Common Stock
Feb 09 2024	SELL Payment of exercise price or tax liability	$351,719 $422.74 p/Share	832 Reduced 3.34%	24,050 Common Stock
Feb 07 2024	BUY Grant, award, or other acquisition	-	4,743 Added 16.01%	24,882 Common Stock
Feb 06 2024	BUY Grant, award, or other acquisition	-	6,260 Added 23.71%	20,139 Common Stock

Also insider at

ETNB

89bio, Inc. Healthcare

EMA